Middle East And Africa Veterinary Pharmaceutical Market - Strategic Insights and Forecasts (2026-2031)

The Middle East and Africa veterinary pharmaceuticals market is forecast to grow at a CAGR of 6.1%, reaching USD 469.2 million in 2031 from USD 348.7 million in 2026.

The demand drivers in the Middle East and Africa veterinary pharmaceutical market center on the intensification of commercial livestock production and the elevation of food security mandates. Dependency on imported vaccines and antibiotics remains a primary market characteristic, though local capacity in Saudi Arabia, Egypt, and South Africa is expanding. Regulatory influence is increasing as authorities such as the Saudi Food and Drug Authority (SFDA) and the Emirates Drug Establishment (EDE) implement stricter traceability and antimicrobial resistance (AMR) guidelines. Strategic importance is anchored to the "One Health" approach, where animal health is directly linked to human public health outcomes and economic stability.

Market Dynamics

Drivers

• Food Security Mandates: Regional governments are subsidizing veterinary medicines to protect national livestock assets from endemic parasitic threats.

• Commercial Farm Scaling: Large-scale poultry and dairy operations are replacing subsistence farming, which is necessitating the use of bulk injectable and water-soluble medications.

• Technological Integration: The adoption of IoT-based health monitoring in cattle is enabling earlier therapeutic intervention, thereby increasing the frequency of pharmaceutical consumption.

• Pet Care Sophistication: Urbanized populations in the UAE and Saudi Arabia are spending more on preventive care, which is accelerating the uptake of companion animal vaccines and wellness supplements.

Restraints and Opportunities

• Cold-Chain Constraints: Inadequate refrigeration infrastructure in sub-Saharan Africa is limiting the distribution of temperature-sensitive biologics and vaccines.

• Antimicrobial Resistance (AMR) Regulations: New federal laws in the UAE and Kenya are restricting the over-the-counter sale of antibiotics, which is creating a temporary volume gap in the retail segment.

• Localized Manufacturing Opportunities: Incentives for domestic production in Saudi Arabia’s Vision 2030 are allowing local firms to capture share from traditional importers.

• Drought-Resilient Pharmaceuticals: Ongoing climate variability in East Africa is creating demand for metabolic modifiers and vitamins that support animal health during resource scarcity.

Supply Chain Analysis

The supply chain for veterinary pharmaceuticals in the Middle East and Africa is undergoing a structural realignment toward decentralized distribution. Historically, international manufacturers rely on a single primary distributor per country, but the growth of commercial farming is forcing the adoption of direct-to-farm logistics. Raw material sourcing remains heavily dependent on API imports from India and China, which subjects local manufacturers like VAPCO and UNIVET to global price fluctuations. Wholesale distributors are now integrating cold-chain monitoring technologies to comply with evolving SFDA and EDE standards. These distributors are expanding their roles by offering technical training to veterinarians to ensure product efficacy at the point of use. Final delivery is shifting toward hospital pharmacies and specialized retail outlets as governments tighten regulations on the sale of prescription-only medicines. Structural bottlenecks persist at customs ports where regulatory delays often impact the shelf-life of biological products.

Government Regulations

Key Developments

• February 2026: Norbrook Laboratories achieved a major breakthrough by exporting Kenyan-manufactured veterinary medicines, including antiparasitics like Levafas Diamond and Noromectin, to the MENA region. This marks the first Africa-to-global shipment of its kind.

• May 2025: Vetanco partnered with Saudi Arabia’s ARASCO to introduce advanced animal health technologies and feed additives. This collaboration focuses on enhancing disease prevention and performance outcomes for the region's expanding livestock sector.

• October 2024: The UAE Government issued Federal Decree-Law No. 38 to regulate pharmaceutical establishments, which mandates stricter supply chain security and innovation protection for veterinary and human medical products.

Market Segmentation

By Type

Oral formulations represent the primary delivery mechanism for large-scale herd management due to their ease of administration through feed and water systems. Livestock producers are increasingly utilizing water-soluble powders to manage respiratory and gastrointestinal infections in poultry and cattle. Injectable pharmaceuticals are maintaining a critical role in acute care and therapeutic intervention where rapid onset is necessary. Veterinarians are shifting toward long-acting injectables to reduce the frequency of animal handling and labor costs. Topical treatments, including pour-on parasiticides, are gaining traction in cattle farming to combat endemic tick-borne diseases. Ophthalmic and auricular products are experiencing rising demand in the companion animal segment as pet owners seek specialized care for inflammatory conditions. Manufacturers are introducing more palatable oral liquids to improve compliance in feline and canine patients. Structural changes in the retail sector are forcing a shift from bulk packaging to unit-dose formats to prevent drug wastage.

By Animal Type

Production animals dominate the regional market volume because livestock remains the foundation of rural economies and national food security. Poultry producers are escalating their consumption of vaccines and anti-coccidials to mitigate the risks associated with high-density farming. Cattle farmers are increasing their use of anthelmintics to improve weight gain and milk yield in both traditional and commercial setups. Companion animals are emerging as a high-value segment in urban centers where pet owners are adopting Western-style healthcare behaviors. Canine and feline patients are requiring more sophisticated medications, including analgesics and anti-inflammatory drugs for age-related conditions. Equine health is a strategically distinct segment in the Middle East, where high-value racing and breeding horses require premium-grade pharmaceuticals. Small ruminant health remains a focus for government-led vaccination campaigns in North and East Africa. Structural urbanization is expanding the pet care infrastructure, which is pulling more specialized pharmaceutical products into the region.

By End User

Veterinary hospitals and clinics are functioning as the primary gateway for prescription-based pharmaceuticals and diagnostic-led treatments. These facilities are expanding their diagnostic capabilities, which is leading to more accurate drug selection and higher therapeutic success rates. Animal farms are increasingly purchasing medications through direct-to-farm supply channels to manage costs and ensure a steady supply of essential antibiotics. Commercial poultry and dairy farms are integrating pharmacy management systems to track drug usage and residue withdrawal periods. Government agencies and non-governmental organizations are playing a major role in the distribution of vaccines in remote areas. Retail pharmacies are evolving into specialized animal health outlets to meet the needs of small-scale farmers and urban pet owners. Large-scale livestock operations are forcing manufacturers to offer technical support services alongside their pharmaceutical portfolios. This shift is resulting in a more professionalized procurement process that prioritizes product efficacy and manufacturer reputation.

Regional Analysis

The Middle East and Africa veterinary pharmaceutical market is bifurcating into two distinct demand profiles: high-value preventive care in the GCC and mass-scale livestock protection in Sub-Saharan Africa. Saudi Arabia is leading regional market development as the government implements Vision 2030 initiatives to localize pharmaceutical manufacturing. The Saudi Ministry of Environment, Water, and Agriculture is encouraging private sector participation in veterinary R&D, which is resulting in new partnerships between local firms like SPI and multinational entities. The UAE is positioning itself as a hub for veterinary innovation following the enactment of new pharmaceutical laws that streamline drug registration and protect intellectual property. Demand in the UAE is shifting heavily toward the companion animal segment as the expatriate population increases investment in pet wellness and preventive medicine.

South Africa remains the most mature market in Sub-Saharan Africa, possessing a robust regulatory framework and a strong presence of multinational players like MSD Animal Health and Zoetis. The South African market is currently navigating stricter antimicrobial stewardship, which is forcing a transition toward alternative feed additives and vaccines. In East Africa, Kenya and Ethiopia are experiencing growth driven by the commercialization of the dairy and poultry sectors. The World Organization for Animal Health is supporting these regions with cold-chain infrastructure, which is increasing the availability of vaccines for diseases like Peste des Petits Ruminants (PPR).

Egypt is maintaining its status as a critical manufacturing base for the North African region, with local companies like UNIVET expanding their export footprint into neighboring markets. The Egyptian market is facing inflationary pressures that are shifting demand toward locally produced, cost-effective generics. Nigeria is showing significant potential due to its large livestock population, although infrastructure gaps continue to constrain the distribution of high-value pharmaceuticals. Regional trade blocs, such as the SADC, are working to eliminate these constraints by harmonizing regulatory standards, which is facilitating more consistent cross-border drug availability. The overall regional landscape is moving toward a more structured, regulatory-compliant ecosystem that favors manufacturers with strong local distribution partnerships.

Competitive Landscape

• United Company For Veterinary Medicines Industry (UNIVET)

• Montajat Company

• MSD Animal Health (Merck & Co., Inc.)

• Vetoquinol India Animal Health Pvt Ltd.

• VAPCO Manufacturing Co., Ltd.

• Saudi Pharmaceutical Industries (SPI)

• Pharma Care Leading Manufacturing Co. Ltd.

• The Arab Pesticides and Veterinary Drugs Mfg. Co (Mobedco)

• Salehiya

• Merck & Co., Inc. (MSD)

MSD Animal Health (Merck & Co., Inc.)

MSD Animal Health is strategically distinct due to its integration of biopharmaceutical solutions with advanced livestock monitoring technologies. The company is actively deploying data-driven health platforms in the Middle East to complement its traditional vaccine and antibiotic portfolios. Demand for its high-tech solutions is rising as large-scale dairy farms in Saudi Arabia seek to improve reproductive efficiency and disease detection. MSD is maintaining its market leadership by focusing on the "One Health" agenda and antimicrobial stewardship. This strategy is resulting in the introduction of novel biologics that reduce the need for conventional anti-infectives.

VAPCO Manufacturing CO. Ltd.

VAPCO is strategically distinct as a leading regional manufacturer with a diverse portfolio covering both veterinary pharmaceuticals and agricultural chemicals. The company is expanding its injectable and oral liquid production lines to meet the growing needs of the GCC livestock sector. Its local manufacturing presence in Jordan allows it to offer competitive pricing and faster lead times compared to international importers. VAPCO is currently focusing on specialized formulations, such as anti-coccidials and vitamins, to address the specific climatic challenges of the Middle East. This localization is enabling it to capture market share in the government tender segment.

United Company For Veterinary Medicines Industry (UNIVET)

UNIVET is strategically distinct through its strong focus on the North African and Levant markets, utilizing its Egyptian manufacturing base to provide affordable veterinary generics. The company is investing in GMP-certified facilities to elevate its quality standards and compete with global brands. Its product range is shifting toward high-frequency treatments for poultry and cattle, reflecting the intensifying demand for animal protein in its core markets. UNIVET is leveraging its regional distribution network to overcome logistical hurdles that often affect imported goods. This approach is resulting in high brand loyalty among small and medium-scale livestock producers.

Analyst View

The Middle East and Africa veterinary pharmaceutical market is transitioning from a remedial to a preventive model. Regulatory modernization and the scaling of commercial livestock operations are the primary forces reshaping the competitive and structural landscape through 2031.

Middle East And Africa Veterinary Pharmaceutical Market Scope: